

Amber N Mcelroy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4391823/publications.pdf>

Version: 2024-02-01

11
papers

903
citations

840776

11
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

1222
citing authors

#	ARTICLE	IF	CITATIONS
1	Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing. <i>Molecular Therapy</i> , 2022, 30, 130-144.	8.2	23
2	Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. <i>Journal of Investigative Dermatology</i> , 2020, 140, 338-347.e5.	0.7	69
3	Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. <i>Nature Communications</i> , 2019, 10, 5222.	12.8	135
4	CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 946.	4.1	19
5	CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1269.	4.1	23
6	CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. <i>Npj Regenerative Medicine</i> , 2016, 1, .	5.2	74
7	CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. <i>Stem Cells and Development</i> , 2016, 25, 1591-1603.	2.1	24
8	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. <i>Molecular Therapy</i> , 2016, 24, 570-581.	8.2	168
9	Fanconi Anemia Gene Editing by the CRISPR/Cas9 System. <i>Human Gene Therapy</i> , 2015, 26, 114-126.	2.7	94
10	TALEN-based Gene Correction for Epidermolysis Bullosa. <i>Molecular Therapy</i> , 2013, 21, 1151-1159.	8.2	232
11	Keratinocytes from Induced Pluripotent Stem Cells in Junctional Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2013, 133, 562-565.	0.7	33